Lymphoma Clinical Trials

Showing 681-700 of 2,926 trials

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

NCT06137144

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

LymphomaNon-HodgkinHodgkin Lymphoma

AstraZeneca110 participantsStarted Jan 2024

Miami, Florida, United States • Atlanta, Georgia, United States • Boston, Massachusetts, United States +17 more locations

WITHDRAWNNA

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT05106192

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.

Mycosis Fungoides of Skin (Diagnosis)Cutaneous T-cell LymphomaNon Hodgkin Lymphoma+3 more

Case Comprehensive Cancer CenterStarted Apr 2022

Cleveland, Ohio, United States

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Related Searches

Clonal Hematopoiesis of Immunological Significance

The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease

The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study

Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.

Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma

RGL-305+ Lymphoma + Exploratory Clinical Study

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma